Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Zegkos

Showing results (31-40 of 66) with videos related to

Pageof 7
Sort By:
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese|May 11, 2020
A novel desmoplakin mutation associated with left dominant arrhythmogenic cardiomyopathy and cutaneous phenotypeGeorgios Efthimiadis, Thomas Zegkos, Soultana Meditskou, et al.
Hellenic Journal of Nuclear Medicine|August 1, 2022
A novel quantitative method for assessing the therapeutic response to Tafamidis therapy in patients with cardiac TTR amyloidosis. A preliminary reportArgiris Doumas, Thomas Zegkos, Despoina Parcharidou, et al.
JACC. Cardiovascular Interventions|August 18, 2022
Low Molecular Weight Heparin in Improving RAO After Transradial Coronary Catheterization: The LOW-RAO Randomized StudyMatthaios Didagelos, Areti Pagiantza, Thomas Zegkos, et al.
Postepy W Kardiologii Interwencyjnej = Advances in Interventional Cardiology|February 26, 2026
In-hospital prognosis of high bleeding risk patients with an acute coronary syndrome and successful percutaneous coronary intervention: a single-center real-world registryCharalampos Kakderis, Matthaios Didagelos, Thomas Zegkos, et al.
Plos One|November 8, 2023
Periostin is overexpressed, correlated with fibrosis and differs among grades of cardiomyocyte hypertrophy in myectomy tissue of patients with hypertrophic cardiomyopathyNikolaos S Ioakeimidis, Antonios Pitsis, Thomas Zegkos, et al.
American Journal of Medical Genetics. Part A|March 12, 2026
The Novel ACTC1 p.Gly50Ser Variant Is Associated With Arrhythmia and Secondary Features of HCM Without HypertrophyThomas D Gossios, Dimitrios Ntelios, Thomas Zegkos, et al.
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese|February 22, 2017
Atrial fibrillation in hypertrophic cardiomyopathy: A turning point towards increased morbidity and mortalityThomas Zegkos, Georgios K Efthimiadis, Despoina G Parcharidou, et al.
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese|February 12, 2023
Prevalence, characteristics, and natural history of apical phenotype in a large cohort of patients with hypertrophic cardiomyopathyPavlos Rouskas, Thomas Zegkos, Dimitris Ntelios, et al.
Future Cardiology|August 16, 2021
Low-molecular-weight heparin in radial artery occlusion treatment: the LOW-RAO randomized studyMatthaios Didagelos, Areti Pagiantza, Thomas Zegkos, et al.
Heart Failure Reviews|October 28, 2024
The many faces of SCN5A pathogenic variants: from channelopathy to cardiomyopathyIoannis Vouloagkas, Andrea Agbariah, Thomas Zegkos, et al.
Pageof 7

Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese|May 11, 2020
A novel desmoplakin mutation associated with left dominant arrhythmogenic cardiomyopathy and cutaneous phenotypeGeorgios Efthimiadis, Thomas Zegkos, Soultana Meditskou, et al.
Hellenic Journal of Nuclear Medicine|August 1, 2022
A novel quantitative method for assessing the therapeutic response to Tafamidis therapy in patients with cardiac TTR amyloidosis. A preliminary reportArgiris Doumas, Thomas Zegkos, Despoina Parcharidou, et al.
JACC. Cardiovascular Interventions|August 18, 2022
Low Molecular Weight Heparin in Improving RAO After Transradial Coronary Catheterization: The LOW-RAO Randomized StudyMatthaios Didagelos, Areti Pagiantza, Thomas Zegkos, et al.
Postepy W Kardiologii Interwencyjnej = Advances in Interventional Cardiology|February 26, 2026
In-hospital prognosis of high bleeding risk patients with an acute coronary syndrome and successful percutaneous coronary intervention: a single-center real-world registryCharalampos Kakderis, Matthaios Didagelos, Thomas Zegkos, et al.
Plos One|November 8, 2023
Periostin is overexpressed, correlated with fibrosis and differs among grades of cardiomyocyte hypertrophy in myectomy tissue of patients with hypertrophic cardiomyopathyNikolaos S Ioakeimidis, Antonios Pitsis, Thomas Zegkos, et al.
American Journal of Medical Genetics. Part A|March 12, 2026
The Novel ACTC1 p.Gly50Ser Variant Is Associated With Arrhythmia and Secondary Features of HCM Without HypertrophyThomas D Gossios, Dimitrios Ntelios, Thomas Zegkos, et al.
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese|February 22, 2017
Atrial fibrillation in hypertrophic cardiomyopathy: A turning point towards increased morbidity and mortalityThomas Zegkos, Georgios K Efthimiadis, Despoina G Parcharidou, et al.
Hellenic Journal of Cardiology : HJC = Hellenike Kardiologike Epitheorese|February 12, 2023
Prevalence, characteristics, and natural history of apical phenotype in a large cohort of patients with hypertrophic cardiomyopathyPavlos Rouskas, Thomas Zegkos, Dimitris Ntelios, et al.
Future Cardiology|August 16, 2021
Low-molecular-weight heparin in radial artery occlusion treatment: the LOW-RAO randomized studyMatthaios Didagelos, Areti Pagiantza, Thomas Zegkos, et al.
Heart Failure Reviews|October 28, 2024
The many faces of SCN5A pathogenic variants: from channelopathy to cardiomyopathyIoannis Vouloagkas, Andrea Agbariah, Thomas Zegkos, et al.
Pageof 7